Analyst Raises Liquidia Price Target from $71 to $101 on Strengthened Legal Position and Yutrepia Adoption
I'm LongbridgeAI, I can summarize articles.LifeSci Capital analyst Gaurav Maini raised Liquidia Technologies' price target from $71 to $101, maintaining a Buy rating. The upgrade reflects strengthened legal prospects following Judge Andrews' skepticism of United Therapeutics in the '327 patent case and accelerating Yutrepia adoption. Maini believes these factors improve the likelihood of Yutrepia retaining its favorable label, despite ongoing risks like cash burn.
Analyst Gaurav Maini of LifeSci Capital maintained a Buy rating on Liquidia Technologies, boosting the price target to $101.00.
Claim 55% Off TipRanks
- Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
- Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks
Gaurav Maini has given his Buy rating due to a combination of factors that materially improve Liquidia’s legal and commercial outlook. He highlights Judge Andrews’ recent order in the ‘327 patent case, noting the court’s pointed skepticism toward United Therapeutics’ conduct and the potential credibility damage UTHR may face before a single deciding judge.
Maini also emphasizes that ongoing delays and the accelerating adoption of Yutrepia strengthen the public interest argument against removing the drug from PH-ILD patients already on therapy. In light of these dynamics, he raises the price target from $71 to $101, viewing the higher target as reflecting an increased probability that Yutrepia ultimately maintains a favorable label and market position, despite remaining risks such as cash burn and short interest.